The short answer
Qualifying a glucosamine supplier means establishing that the proposed source can consistently supply the defined material for your intended use. Start with the product and manufacturing site, review relevant evidence, evaluate analytical reliability and samples, and document the approval and ongoing controls. A licence or certificate alone does not complete the assessment.
In this guide
Key checks
- Qualify the product, site and supply chain together.
- Match evidence to the intended market and application.
- Agree how changes and future batches will be controlled.
Define what you are qualifying
Before collecting certificates, write a short sourcing brief: full ingredient name and salt form, intended application, destination, specification revision and forecast volume. Identify whether the counterparty is the original manufacturer, a distributor or another intermediary. Record the actual manufacturing site and any repacking step.
Set the acceptance decision in advance. A useful review ends with a documented approved source and defined conditions, not simply a folder of certificates. Decide who in procurement, quality and regulatory affairs can approve the material and which open items must be closed first.
Confirm the GSPC product identity ↗Use a risk-based assessment, not a badge count
ICH Q7 and its Q&A describe risk-based supplier evaluation in the API context; the Q&A does not make an on-site audit mandatory in every case. Choose the depth of your assessment according to the material and supply-chain risk, and document your reasoning.
For a US dietary supplement operation, FDA guidance describes a different component-control framework, including conditions for relying on supplier COAs. Do not copy an API qualification checklist into another regulated activity without checking the applicable obligations.
Sources: [1] FDA / ICH Q7 Questions and Answers · [2] FDA dietary supplement CGMP small-entity guide
What evidence should you request?
| Review area | Evidence to request | Decision to record |
|---|---|---|
| Identity & source | Complete ingredient name, salt form, origin and allergen declarations | The proposed material matches your intended specification. |
| Company & site | Legal manufacturer, site address, supply-chain and repacking details | You know which site and parties are being qualified. |
| Manufacturing scope | Current licence and relevant registration / inspection documents | Product, site, activities, dates and issuing authority align. |
| Analytical controls | Signed specification, representative COA and method information | Limits, reporting basis and results can be evaluated. |
| Sample evaluation | Traceable sample and your agreed evaluation plan | Your quality team records the outcome and any conditions. |
| Supply arrangements | Packaging, storage, transport, MOQ and lead-time confirmation | Commercial terms match the technical and logistical need. |
| Ongoing control | Change notification, complaints and traceability arrangements | Responsibilities and escalation routes are agreed. |
How should Chinese API documents be interpreted?
Shuanglin has a Chinese API manufacturing licence. Request the current copy and check the legal entity, manufacturing address, product scope and validity. Review the API registration and GMP inspection documents in the same way: a relevant inspection scope is more useful than an isolated logo or certificate title.
These Chinese documents support source assessment. They do not by themselves establish FDA, EU, TGA or other overseas approval. Likewise, technical cooperation or appreciation from USP should not be presented as USP product certification. Confirm destination-specific documentation directly with your regulatory team.
Request the relevant regulatory and quality documents ↗Connect the paperwork to the material
Agree what the sample is intended to demonstrate and which tests your quality team will perform or outsource. Keep its lot identity connected to the COA and the evaluation record. If your specification differs from the supplier’s, reconcile the differences before treating a pass as an approval.
Ask how the supplier handles out-of-specification findings, deviations, complaints and proposed process or site changes. The answer should identify a communication route and an accountable organisation. An attractive certificate does not answer these operational questions.
Sources: [1] FDA / ICH Q7 Questions and Answers
Explore the quality-control facilities ↗Approve with clear conditions and maintain the file
Record the approved material, manufacturer and site; the agreed specification; the review evidence; and any restrictions or follow-up dates. Make sure a purchase order cannot silently switch the salt form, manufacturing source or specification revision.
For ongoing supply, review the relevant lot documentation and follow your incoming-material controls. Reassess when a significant change or performance issue occurs, and refresh time-limited documents when needed. This turns an initial qualification exercise into a usable purchasing control.
- Who receives a proposed change, and when?
- Which documents accompany a shipment?
- How are lot identity and complaints traced back to the source?
- Which unresolved issue would pause the next order?
Start a focused qualification with Shuanglin
Share the target country, pharmaceutical or supplement application, specification revision and expected volume. Identify the documents and sample evaluation you need. We can then discuss the relevant file, availability, commercial requirements and any NDA arrangements.
The initial inquiry form is intended to start that review. Avoid sending confidential formulation details until a suitable information-sharing arrangement is agreed.
Review GSPC manufacturing information ↗Frequently asked questions
Is a Chinese API licence enough for overseas purchasing approval?
No. Review the licence as one part of the source assessment, then confirm the requirements for your destination, intended application and final product.
Must every supplier undergo an on-site audit?
The appropriate approach depends on the governing framework and your risk assessment. ICH Q7 Q&A does not require an on-site audit in every API supplier evaluation; other situations may have different requirements.
Can a supplier COA replace all incoming testing?
Do not assume that it can. Apply your own approved procedure and the applicable rules on identity testing, supplier qualification and the reliability of supplier results.
Sources & scope
Public references support the technical context. Shuanglin’s current signed specification, batch documents and your own qualification decision govern a purchase. Calculations in this guide are illustrative, not batch test results.
- FDA / ICH Q7 Questions and Answers ↗
API material-supplier evaluation, analytical alignment and the role of risk-based audits.
- FDA dietary supplement CGMP small-entity guide ↗
US supplement component controls and supplier-COA reliance; not a universal market rule.
Move from reading to qualification.
Send your destination, intended use and specification. Tell us which documents or sample evaluation you need.